首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

2050732

雙極性情感障礙情緒穩定劑市場：按藥物類型、適應症、給藥途徑、患者群體、分銷管道和地區分類。

Bipolar Disorder Mood Stabilizers Market, By Drug Type, By Indication, By Route of Administration, By Patient Demographics, By Distribution Channel, By Geography

出版日期: 2026年03月31日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年，用於治療雙極性情感疾患的情緒穩定劑市場規模估計為23億美元，預計2033年將達到27.5億美元。預計從2026年到2033年，該市場將以2.7%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	23億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	2.70%	2033年市場規模預測：	27.5億美元

雙極性情感障礙（也稱為憂鬱症）是一種腦部疾病，其特徵是情緒、精力、活動水平以及日常活動能力出現異常波動。情緒穩定劑是一種用於預防或治療雙極性情感疾患相關極端情緒波動的藥物。近年來，雙極性情感障礙在全球的盛行率不斷上升，以及人們對有效治療方法的認知不斷提高，推動了全球雙極性情感障礙情緒穩定劑市場顯著成長。製藥公司加大研發投入，開發新的治療方法，也是推動市場成長的重要因素。

市場動態

全球雙相情感障礙情緒穩定劑市場的主要驅動力是雙相情感障礙盛行率的不斷上升，而雙相情感障礙的原因包括遺傳因素和環境因素，例如創傷性生活事件和藥物濫用。根據世界衛生組織2025年7月發布的統計數據，全球將有超過4,500萬人患有雙相情感障礙。此外，人們對現有治療方法的認知不斷提高以及醫療保健成本的不斷上漲，促使更多患者尋求醫療協助。同時，持續的創新以及療效更高、耐受性更好的新配方的推出，也促進了市場擴張。然而，精神疾病診斷率和治療率較低，這意味著開發中國家的市場潛力尚未充分開發。品牌藥的高成本也限制了其在價格敏感市場的普及。儘管如此，針對難治性患者的先進藥物的臨床試驗仍在進行中，預計將在預測期內創造新的機會。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數對全球雙相情感障礙情緒穩定劑市場的主要參與者進行了分析：公司亮點、產品系列、主要特徵、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球雙極性情感障礙情緒穩定劑市場報告」旨在為該行業的各種相關人員提供服務，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用全球雙相情感障礙情緒穩定劑市場分析中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第10章競爭格局

Eli Lilly and Company
AstraZeneca PLC
Johnson & Johnson
Pfizer Inc.
AbbVie Inc.
Bristol-Myers Squibb
GlaxoSmithKline
Sanofi SA
Merck & Co.
Teva Pharmaceutical Industries
Novartis AG
Otsuka Pharmaceutical
Lundbeck A/S
Takeda Pharmaceutical Company
Alkermes plc

第11章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第12章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI7877

Bipolar Disorder Mood Stabilizers Market is estimated to be valued at USD 2.30 Bn in 2026 and is expected to reach USD 2.75 Bn by 2033, growing at a compound annual growth rate (CAGR) of 2.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2.30 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	2.70%	2033 Value Projection:	USD 2.75 Bn

Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Mood stabilizers are a class of drugs used to prevent or treat the extreme mood swings associated with bipolar disorder. The global bipolar disorder mood stabilizers market has been gaining significant traction over the past few years, owing to the rising prevalence of bipolar disorder worldwide and growing awareness regarding its effective treatment options. Increasing R&D investments by pharmaceutical companies to develop novel treatment alternatives are also propelling the market growth.

Market Dynamics

The global bipolar disorder mood stabilizers market is primarily driven by the growing prevalence of bipolar disorder caused by genetic and environmental factors such as traumatic life events and substance abuse. As per WHO statistics released in July 2025, over 45 million people worldwide suffer from bipolar disorder. Furthermore, rising awareness about available treatment options and increased healthcare spending are encouraging more patients to seek medical help. Meanwhile, continuous innovations and introduction of new drug formulations with higher efficacy and improved tolerability are helping expand the market reach. However, the market potential is still untapped in underdeveloped economies due to low diagnosis and treatment rates of mental disorders. High costs of branded drugs also limit their adoption in price-sensitive markets. Nonetheless, ongoing clinical trials for advanced drugs, especially for treatment-resistant patients, are expected to introduce new opportunities during the forecast period.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bipolar disorder mood stabilizers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eli Lilly and Company, AstraZeneca PLC, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, GlaxoSmithKline, Sanofi S.A., Merck & Co., Teva Pharmaceutical Industries, Novartis AG, Otsuka Pharmaceutical, H. Lundbeck A/S, Takeda Pharmaceutical Company, and Alkermes plc
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global bipolar disorder mood stabilizers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder mood stabilizers market

Market Segmentation

Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
Lithium
- Lithium Carbonate
- Lithium Citrate
Anticonvulsants
- Valproic Acid/Valproate/Divalproex Sodium
- Lamotrigine
- Carbamazepine
- Oxcarbazepine
- Topiramate
Atypical Antipsychotics
- Aripiprazole
- Olanzapine
- Quetiapine
- Risperidone
- Lurasidone
- Ziprasidone
- Asenapine
Calcium Channel Blockers
Others (Combination Therapies, etc.)
Indication Insights (Revenue, USD Bn, 2021 - 2033)
Bipolar I Disorder
Bipolar II Disorder
Cyclothymic Disorder
Mixed Features Bipolar Disorder
Rapid Cycling Bipolar Disorder
Others
Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
Oral
Parenteral/Injectable
Transdermal
Others
Patient Demographics Insights (Revenue, USD Bn, 2021 - 2033)
Age Groups
Children and adolescents
Adults
Elderly
Gender
Male
Female
Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
Eli Lilly and Company
AstraZeneca PLC
Johnson & Johnson
Pfizer Inc.
AbbVie Inc.
Bristol-Myers Squibb
GlaxoSmithKline
Sanofi S.A.
Merck & Co.
Teva Pharmaceutical Industries
Novartis AG
Otsuka Pharmaceutical
Lundbeck A/S
Takeda Pharmaceutical Company
Alkermes plc

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Bipolar Disorder Mood Stabilizers Market, By Drug Type
- Global Bipolar Disorder Mood Stabilizers Market, By Indication
- Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration
- Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics
- Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel
- Global Bipolar Disorder Mood Stabilizers Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Bipolar Disorder Mood Stabilizers Market, By Drug Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Lithium
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Lithium Carbonate
  - Lithium Citrate
Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Valproic Acid/Valproate/Divalproex Sodium
  - Lamotrigine
  - Carbamazepine
  - Oxcarbazepine
  - Topiramate
Atypical Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Aripiprazole
  - Olanzapine
  - Quetiapine
  - Risperidone
  - Lurasidone
  - Ziprasidone
  - Asenapine
Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others (Combination Therapies, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Bipolar Disorder Mood Stabilizers Market, By Indication, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Bipolar I Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Bipolar II Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Cyclothymic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Mixed Features Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Rapid Cycling Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Parenteral/Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Age Groups
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Children and adolescents
  - Adults
  - Elderly
Gender
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
  - Male
  - Female

8. Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Bipolar Disorder Mood Stabilizers Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Otsuka Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Alkermes plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies